RxDoctor Payments Data

Samantha Nicolini

Physician Assistant · West Islip, NYNPI 1518340918

Payments from drug & device makers

$17,937in general payments, 2019–2025

Across 425 payments — averaging $42.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$7K
  • Incyte Corporation$5K
  • Johnson & Johnson$881
  • Mayne Pharma Commercial LLC$767
  • Dermavant Sciences, Inc.$755
  • LEO Pharma Inc.$708
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$4,80227%
  • Speaking & faculty fees$6,90038%
  • Travel & lodging$100%
  • Food & beverage$5,47431%
  • Education$7514%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,937 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$13,450
Medicare patients
87
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa11$207,603
TremfyaGuselkumab13$195,773
Dupixent SyringeDupilumab33$155,765
OtezlaApremilast19$90,741
Dupixent PenDupilumab15$67,180
OpzeluraRuxolitinib Phosphate23$50,132
VtamaTapinarof11$15,026
Tacrolimus42$4,715
Clobetasol Propionate106$4,272
Ketoconazole141$2,488
Clindamycin Phosphate48$2,067
Azelaic Acid15$1,862
Mometasone Furoate92$1,529
Metronidazole25$1,144
Triamcinolone Acetonide153$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$361$207,60311 claims
Johnson & JohnsonTremfya$881$195,77313 claims
AmgenOtezla$61$90,74119 claims
Incyte CorporationOpzelura$4,897$50,13223 claims
Dermavant Sciences, Inc.Vtama$755$15,02611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in West Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →